The transient receptor potential ankyrin-1 (TRPA1) channel has emerged as an attractive target for development of analgesic and anti-inflammatory drugs. However, drug discovery efforts targeting TRPA1 have been hampered by differences between human and rodent species. Many compounds have been identified to have antagonist activity at human TRPA1 (hTRPA1), but when tested at rat TRPA1 (rTRPA1) and mouse TRPA1 (mTRPA1), they show reduced potency as antagonists, no effect, or agonist activity. These compounds are excluded from further drug development because they cannot be tested in preclinical studies using conventional rat/mouse models. To broaden our understanding of species-specific differences, we cloned and functionally characterized rhesus monkey TRPA1 (rhTRPA1) and compared its pharmacological profile to hTRPA1, rTRPA1, and mTRPA1 channels. The functional activities of a diverse group of TRPA1 ligands (both reactive and nonreactive) were determined in a fluorescent Ca 2ϩ influx assay, using transiently transfected human embryonic kidney 293-F cells. 4-Methyl-N-[2,2,2-trichloro-1-(4-nitro-phenylsulfanyl)-ethyl]-benzamide, menthol, and caffeine displayed species-specific differential pharmacology at TRPA1. The pharmacological profile of the rhTRPA1 channel was found to be similar to the hTRPA1 channel. In contrast, the rTRPA1 and mTRPA1 channels closely resembled each other but were pharmacologically distinct from either hTRPA1 or rhTRPA1 channels. Our findings reveal that TRPA1 function differs between primate and rodent species and suggest that rhesus monkey could serve as a surrogate species for humans in preclinical studies.
Introduction
The transient receptor potential ankyrin-1 (TRPA1) channel is an attractive target for pain and inflammation in drug discovery. It is expressed abundantly in a subpopulation of C-fiber primary afferent neurons that also coexpress the capsaicin receptor transient receptor potential vanilloid-1 and acts as a detector of noxious stimuli in the periphery. In animal studies, activation of TRPA1 by pungent natural products and environmental irritants causes pain and inflammation, and these effects can be blocked by treatment with TRPA1 antagonists or genespecific antisense oligonucleotides McNamara et al., 2007; Petrus et al., 2007) . In airway chemosensory neurons, the TRPA1 channel mediates the irritant responses to many asthma-inducing agents, including oxidizing chemicals in the environment (e.g., chlorine, chloramines, ozone, and acrolein), endogenous reactive oxygen species (e.g., hydrogen peroxide and hypochlorite), and lipid peroxidation products (Andersson et al., 2008; Bessac et al., 2008; Caceres et al., 2009 ). These studies suggest that development of a selective TRPA1 antagonist could be beneficial for the treatment of pain, neurogenic inflammation, and asthma.
Screening and medicinal chemistry efforts have identified numerous TRPA1 antagonists. Some of these, such as (E)-4-(4-chlorophenyl)-3-methyl-but-3-en-2-one oxime (AP18) (Petrus et al., 2007) , 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-N-(4-isopropyl-phenyl)-acetamide (HC-030031) (McNamara et al., 2007; Eid et al., 2008) , and (E)-1-(4-fluoro-phenyl)-2-methyl-pent-1-en-3-one oxime (A-967079) (Chen et al., 2011) , have proven to be invaluable tools for validating TRPA1 as a pain target. AP18, HC-030031, and A-967079 block both human and rodent TRPA1 channels and have been shown to be antinociceptive in rodent pain models. AP18 reversed complete Freund's adjuvant-induced mechanical hyperalgesia in mice (Petrus et al., 2007) , whereas HC-030031 similarly reversed complete Freund's adjuvant-and spinal nerve ligation-induced mechanical hypersensitivity in rats (Eid et al., 2008) . In addition, A-967079 attenuated osteoarthritic pain and neuropathy-induced ice-cold allodynia in rats, without altering noxious cold sensation or body temperature regulation (Chen et al., 2011) . Despite this progress, drug discovery targeting the TRPA1 channel has been hampered by differences between human and rodent species. For instance, a series of structurally related thioaminals have been reported to have antagonist activity at human TRPA1 (hTRPA1), but when tested at rat TRPA1 (rTRPA1), they were either inactive [4-bromo-N-[2,2,2-trichloro-1-(4-chloro-phenylsulfanyl)-ethyl]-benzamide (AMG7160) and 4-nitro-N-[2,2,2- (Klionsky et al., 2007; Chen et al., 2008) . Such compounds have to be excluded from the drug development process because conventional preclinical studies using rodents would not yield useful information.
TRPA1 agonists can be divided into two groups, i.e., reactive and nonreactive, based on their reactivity to nucleophilic cysteine residues. Reactive TRPA1 agonists consist of endogenous ligands, such as 4-hydroxynonenal (4-HNE) (Macpherson et al., 2007; Trevisani et al., 2007) and 15-deoxy-prostaglandin J 2 (15-d-PGJ 2 ) (Cruz-Orengo et al., 2008; Maher et al., 2008) , and pungent natural products, such as mustard oil (MO) (Jordt et al., 2004) , cinnamaldehyde (CA) (Bandell et al., 2004) , and allicin (Bautista et al., 2005; Macpherson et al., 2005) . Nonreactive TRPA1 agonists are a diverse group of ligands that include amphipathic molecules [e.g., trinitrophenol (TNP)] (Hill and Schaefer, 2007) , lipids [e.g., farnesyl thiosalicylic acid (FTS)] (Maher et al., 2008) , and pharmacological agents [e.g., menthol, caffeine, and 3Ј-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597)] Nagatomo and Kubo, 2008; Xiao et al., 2008; Karashima et al., 2009) . Some of these, such as menthol and caffeine, display species-specific differential pharmacology at TRPA1. Menthol activates hTRPA1 (Xiao et al., 2008) but has a bimodal action at mouse TRPA1 (mTRPA1) that can lead to channel block at high concentrations (Karashima et al., 2009) . Caffeine is an agonist at mTRPA1 but an antagonist at hTRPA1 (Nagatomo and Kubo, 2008) .
In the present study, species-specific differences in TRPA1 function were examined in greater detail. A diverse group of known TRPA1 ligands (both reactive and nonreactive) were tested for functional activity at hTRPA1, rTRPA1, and mTRPA1 channels in vitro. Furthermore, to broaden our understanding of species-specific differences, we cloned and functionally characterized rhesus monkey TRPA1 (rhTRPA1) and compared its pharmacological profile to hTRPA1, rTRPA1, and mTRPA1 channels. We show here that the pharmacological profile of the rhTRPA1 channel is similar to the hTRPA1 channel but is distinctly different from the rTRPA1 and mTRPA1 channels.
Materials and Methods
Molecular Biology and Transient Expression. Full-length cDNAs of hTRPA1 (GenBank accession number NM_007332), rhTRPA1 (GenBank accession number XP_001083172), rTRPA1 (GenBank accession number NM_207608), and mouse TRPA1 (GenBank accession number NM_177781) were cloned in pcDNA3.1/V5-His Topo vector (Invitrogen, Carlsbad, CA). Transient transfections of HEK293-F cells were carried out using the FreeStyle 293 expression system (Invitrogen), as described previously . For electrophysiological studies, plasmid DNAs for rhTRPA1 and green fluorescent protein were cotransfected.
Electrophysiology. Whole-cell recordings were performed on HEK293-F cells cotransfected with rhTRPA1 and green fluorescent protein, as described previously . In brief, cells were held at a membrane potential of Ϫ60 mV and perfused in a nominal Ca 2ϩ -free external solution to prevent desensitization. External and internal solutions contained 140 mM NaCl, 2 mM MgCl 2 , 5 mM EGTA, and 10 mM HEPES (adjusted to 300 mOsmol/l, pH 7.4, with NaOH). Currents were elicited by MO activation. Data were sampled at 2 kHz, filtered at 1 kHz, and analyzed using pCLAMP 9 software (Molecular Devices, Sunnyvale, CA). Ca 2؉ Influx Assay. The potencies of TRPA1 agonists and antagonists were determined in a fluorescent Ca 2ϩ influx assay, as described previously (Bianchi et al., 2007; Chen et al., 2007) . The cells were loaded with a Ca 2ϩ chelating fluorescent dye before testing (FLIPR calcium assay kit, part number R8033; Molecular Devices). Changes in fluorescence were recorded in a fluorometric imaging plate reader (FLIPR) (Molecular Devices) ( EX ϭ 488 nm; EM ϭ 540 nm). The response to agonists (peak increase in fluorescence over baseline) was expressed as a percentage of the maximal response to MO. For antagonists, the response to MO was measured after a 3.5-min treatment period and expressed as a percentage of the control response to MO (in the absence of antagonist). The concentrations of MO used to activate the TRPA1 channel (30 M for hTRPA1, rTRPA1, and mTRPA1; 120 M for rhTRPA1) were near the EC 80 for each species. The concentration-effect data were curve fit to a fourparameter logistic Hill equation to derive the EC 50 and IC 50 values (GraphPad Prism; GraphPad Software Inc., San Diego, CA).
Reagents. MO, CA, TNP, menthol, caffeine, and ruthenium red were obtained from Sigma-Aldrich (St. Louis, MO). 4-HNE was acquired from Calbiochem (San Diego, CA). 15-d-PGJ 2 , FTS, and URB597 were obtained from Cayman Chemical (Ann Arbor, MI). CMP1, AP18, HC-030031, and A-967079 were synthesized in house (Abbott Laboratories, Abbott Park, IL).
Results
Functional Characterization of rhTRPA1 Channel. rhTRPA1 channel function was determined by whole-cell recordings and Ca 2ϩ influx assay. In whole-cell recordings, cells transiently transfected with rhTRPA1 and green fluorescent protein were held at Ϫ60 mV and perfused in a nominally Ca 2ϩ -free external solution to prevent desensitization. Inward currents were induced in response to MO in a concentration-dependent manner, with an EC 50 ϭ 506 M (Fig. 1, A and B) . Furthermore, the MO-induced currents were blocked by the selective TRPA1 antagonist A-967079 (Fig. 1C) . When 1 mM MO was applied to activate the chan-nel, the IC 50 value of A-967079 was 1.63 M (Fig. 1D) . Likewise, in the Ca 2ϩ influx assay, MO activated rhTRPA1 and increased Ca 2ϩ influx in a concentration-dependent manner (EC 50 ϭ 74.7 M) (Fig. 1E) , and the response to 120 M MO was blocked by A-967079 (IC 50 ϭ 0.60 M) (Fig. 1F) . Together, these results indicate that the cloned rhTRPA1 channel is functional.
Species Comparison of Reactive TRPA1 Agonists. A small group of reactive ligands, i.e., MO, CA, 4-HNE, and 15-d-PGJ 2 , was tested for agonist activity at hTRPA1, rhTRPA1, rTRPA1, and mTRPA1 channels, using the Ca 2ϩ influx assay. MO was found to be the most potent at hTRPA1 (EC 50 ϭ 8.2 M) and also showed the highest efficacy in the Ca 2ϩ influx assay ( Fig. 2A ; Table 1 ). It was followed in order of potency by 4-HNE (EC 50 ϭ 9.9 M), CA (EC 50 ϭ 12.5 M), and 15-d-PGJ 2 (EC 50 ϭ 40.4 M). The same compounds were also found to activate the rhTRPA1 channel. However, their potencies were markedly lower at rhTRPA1 ( Fig. 2B ; Table 1 ). MO was 7.5-fold less potent at rhTRPA1 (EC 50 ϭ 74.7 M) than at hTRPA1. Rank-order potency at rhTRPA1 was CA Ͼ MO Ն 4-HNE Ͼ 15-d-PGJ 2 . Both rTRPA1 and mTRPA1 channels were activated by the reactive TRPA1 ligands, but rank-order potency differed from the hTRPA1 channel. The potency of MO at rTRPA1 was about the same as its potency at hTRPA1 (EC 50 ϭ 9.0 M). However, MO was not the most potent and was surpassed in potency by CA and 4-HNE ( Fig. 2C ; Table 1 ). Rankorder potency at rTRPA1 was CA Ն 4-HNE Ͼ MO Ͼ 15-d-PGJ 2 . Likewise, at mTRPA1, MO was less potent than CA and approximately equipotent with 4-HNE ( Fig. 2D ; Table 1 ). Rankorder potency at mTRPA1 was CA Ͼ MO Ն 4-HNE Ͼ 15-d-PGJ 2 .
Species Comparison of Nonreactive TRPA1 Agonists. The ability of several nonreactive ligands, i.e., FTS, URB597, and TNP, to activate the TRPA1 channel was also compared across species. All were found to open the hTRPA1 channel, and of these, FTS was the most potent, showing a higher potency (EC 50 ϭ 4.9 M) and efficacy (106%) than MO in the Ca 2ϩ influx assay ( Fig. 2A ; Table 1 ). It was followed in order of potency by URB597 (EC 50 ϭ 7.5 M) and TNP (EC 50 ϭ 107 M). The same compounds were also found to open the rhTRPA1 channel, with lower potencies ( Fig. 2B ; Table 1 ). FTS was 34-fold less potent at rhTRPA1 (EC 50 ϭ 167 M) than at hTRPA1. Rank-order potency at rhTRPA1 was FTS Ն URB597 Ͼ TNP. Both rTRPA1 and mTRPA1 channels were activated by the nonreactive TRPA1 ligands, but rank-order potency was distinctly different from the hTRPA1 channel. At rTRPA1, TNP was the most potent (EC 50 ϭ 71.2 M), and it was followed in order of potency by FTS (EC 50 ϭ 102 M) and URB597 (EC 50 ϭ 129 M) ( Fig. 2C ; Table 1 ). Rank-order potency at mTRPA1 was TNP Ͼ URB597 Ն FTS ( Fig. 2D ; Table 1 ). A select group of antagonists, i.e., AP18, HC-030031, A-967079, and ruthenium red, was tested for ability to block activation of the TRPA1 channel. These compounds completely blocked the response to MO at hTRPA1, rhTRPA1, rTRPA1, and mTRPA1 channels (Fig. 3, A-D, respectively) . Rank-order potency of the TRPA1 antagonists was generally the same across species (Table 2) . A-967079 was the most potent, and it was followed in order of potency by HC-030031, AP18, and ruthenium red.
Species-Specific Differential Pharmacology at TRPA1. CMP1, menthol, and caffeine displayed species-specific differences in activation and blockade of the TRPA1 channel. CMP1 was found to have no agonist activity at hTRPA1 in the Ca 2ϩ influx assay. Instead, it showed potent antagonist activity and completely blocked the response to 30 M MO (IC 50 ϭ 1.0 M) (Fig. 4 , A and F; Table 2 ). CMP1 was also found to be a potent antagonist of the rhTRPA1 channel. It showed no agonist activity at rhTRPA1 but completely blocked the response to 120 M MO (IC 50 ϭ 2.7 M) (Fig. 4 , B and F; Table 2 ). On the other hand, CMP1 was found to have robust agonist activity at rTRPA1 (EC 50 ϭ 0.88 M) (Fig. 4 , C and E; Table 1 ) and mTRPA1 (EC 50 ϭ 0.93 M) (Fig. 4 , D and E; Table 1 ) and did not inhibit the response to 30 M MO, even at high micromolar concentrations.
Menthol was found to have robust agonist activity at hTRPA1 (EC 50 ϭ 278 M) (Fig. 5 , A and E; Table 1 ). It was solely an agonist of the hTRPA1 channel and did not inhibit the response to 30 M MO up to 1 mM. However, when tested at rhTRPA1, menthol was found to have a bimodal action. Menthol activated the rhTRPA1 channel and increased Ca 2ϩ influx in a concentration-dependent manner up to 1 mM (EC 50 Ͼ 300 M) (Fig. 5 , B and E; Table 1 ). However, the highest concentration tested (1 mM) partially inhibited the response to 120 M MO (Fig. 5, B and F) . Menthol was also found to have a bimodal action at rTRPA1 and mTRPA1, activating the channels at low micromolar concentrations but blocking them at high concentrations. Menthol activated the rTRPA1 and mTRPA1 channels and increased Ca 2ϩ influx in a concentration-dependent manner up to 100 M (EC 50 ϭ 7.1 and 5.2 M, respectively) (Fig. 5, C-E; Table 1 ). Increasing the concentration of menthol further to 0.3 and 1 mM reduced the peak Ca 2ϩ influx and also partially inhibited the response to 30 M MO (IC 50 ϭ 511 and 951 M, respectively) (Fig. 5, C , D, and F; Table 2 ).
Caffeine was found to have no agonist activity at hTRPA1. However, at the highest concentration tested (1 mM), it partially inhibited the response to 30 M MO (IC 50 ϭ 988 M) (Fig. 6 , A and F; Table 2 ). Caffeine was also found to be a weak antagonist of the rhTRPA1 channel. It showed no agonist activity at rhTRPA1 but weakly inhibited the response to 120 M MO (IC 50 Ͼ 1 mM) (Fig. 6 , B and F; Table 2 ). In contrast, caffeine was found to have weak agonist activity at rTRPA1 (EC 50 ϭ 95.9 M) (Fig. 6, C 
Discussion
Species differences between human and rodent TRPA1 have previously been identified by us (Chen et al., 2008; Chen and Kym, 2009) ) were recorded in a FLIPR-based Ca 2ϩ influx assay. Cells were treated with different concentrations of CMP1 for a 3.5-min period, and MO was added 3.5 min later (30 M for human, rat, and mouse TRPA1; 120 M for rhesus monkey TRPA1). CMP1 was a potent activator of rat and mouse TRPA1 but blocked human and rhesus monkey TRPA1. E, concentration-effect curves for activation of the TRPA1 channel by CMP1. These data are expressed as a percentage of the maximal response to MO and represent the means Ϯ S.E.M. for three or more determinations. F, concentration-effect curves for blockade of the TRPA1 channel by CMP1. These data are expressed as a percentage of the control response to MO and represent the means Ϯ S.E.M. for three or more determinations. To further explore the scope of these species differences, we cloned and functionally characterized the TRPA1 channel from another primate species, i.e., rhesus monkey. The rhTRPA1 channel showed a robust response to MO in whole-cell recordings and Ca 2ϩ influx assay, and, furthermore, the response was completely blocked by A-967079. An in-depth pharmacological characterization of rhTRPA1 was performed, and its profile was compared to hTRPA1, rTRPA1, and mTRPA1 channels. To our knowledge, this is the first time that a primate TRPA1 channel other than human has been characterized pharmacologically.
All of the TRPA1 channels that we studied, human, rhesus monkey, rat, and mouse, were activated by endogenous ligands (4-HNE and 15-d-PGJ 2 ) and also by a wide assortment of reference agonists (MO, CA, FTS, URB597, TNP, and menthol). This suggests that hTRPA1, rhTRPA1, rTRPA1, and mTRPA1 channels share a common mechanism of activation that is conserved across species. Functional conservation of TRPA1 is widespread throughout the animal kingdom, including invertebrates and vertebrates, and is thought to be an ancient protective mechanism for detection and avoidance of tissue-damaging chemical agents (Kang et al., 2010) .
We determined that the pharmacological profile of the rhTRPA1 channel was similar to the hTRPA1 channel. Ligands that showed agonist activity at hTRPA1 (both reactive and nonreactive) were found to have agonist activity at rhTRPA1. In addition, compounds that exhibited antagonist activity at hTRPA1 were also found to block rhTRPA1. The similarity between hTRPA1 and rhTRPA1 can be attributed to their high sequence identity (97%). Yet, some differences were detected between rhTRPA1 and hTRPA1. 4-HNE and 15-d-PGJ 2 showed reduced potencies at rhTRPA1 (12-and Ͼ7-fold, respectively), . Changes in fluorescence (RFU) were recorded in a FLIPR-based Ca 2ϩ influx assay. Cells were treated with different concentrations of menthol for a 3.5-min period, and MO was added 3.5 min later (30 M for human, rat, and mouse TRPA1; 120 M for rhesus monkey TRPA1). Menthol activated TRPA1. At high concentrations, however, it also blocked rhesus monkey, rat, and mouse TRPA1, but not human TRPA1. E, concentration-effect curves for activation of the TRPA1 channel by menthol. These data are expressed as a percentage of the maximal response to MO and represent the means Ϯ S.E.M. for three or more determinations. F, concentration-effect curves for blockade of the TRPA1 channel by menthol. These data are expressed as a percentage of the control response to MO, and represent the means Ϯ S.E.M. for three or more determinations.
suggesting that higher levels of these lipids might be required to activate the channel in situ. Reduced potencies were also seen for several reference agonists (MO, FTS, URB597, and TNP). Another difference was evident for menthol. Menthol was solely an agonist at hTRPA1. However, at rhTRPA1, it had a bimodal action, partially blocking the response to MO at 1 mM. The reasons for these differences are unknown at the present time.
rTRPA1 and mTRPA1 channels closely resembled each other but were pharmacologically distinct from either hTRPA1 or rhTRPA1 channels. Ligands that showed agonist or antagonist activity at rTRPA1 were also found to have the same functional activity at mTRPA1. In addition, the potencies of the ligands, and rank-order potencies, were nearly identical at rTRPA1 and mTRPA1. Dramatic differences were detected, though, between primate and rodent species. At hTRPA1 and rhTRPA1, CMP1 and caffeine were antagonists that blocked MO activation of the channels, whereas at rTRPA1 and mTRPA1, the same compounds were agonists that activated the channels. Menthol exhibited agonist activity across species. However, the potency of menthol was markedly higher and efficacy lower at rTRPA1 and mTRPA1. In addition, we have routinely observed substantial species-specific differences in real-life drug screening (B. R. Bianchi and J. Chen, unpublished data) . Many "hits," identified to have antagonist activity at hTRPA1, have reduced potency as antagonists, no effect, or switch to agonist activity at rodent TRPA1. However, hTRPA1 and rhTRPA1 activities are generally consistent.
Species differences between primate and rodent can be attributed to their relatively low sequence identify. At the amino acid level, hTRPA1 and rhTRPA1 are 97% identical, rTRPA1 and mTRPA1 are 97% identical, whereas primate and rodent channels . Changes in fluorescence (RFU) were recorded in a FLIPR-based Ca 2ϩ influx assay. Cells were treated with different concentrations of caffeine for a 3.5-min period, and MO was added 3.5 min later (30 M for human, rat, and mouse TRPA1; 120 M for rhesus monkey TRPA1). Caffeine activated rat and mouse TRPA1 but blocked human and rhesus monkey TRPA1. E, concentration-effect curves for activation of the TRPA1 channel by caffeine. These data are expressed as a percentage of the maximal response to MO and represent the means Ϯ S.E.M. for three or more determinations. F, concentration-effect curves for blockade of the TRPA1 channel by caffeine. These data are expressed as a percentage of the control response to MO and represent the means Ϯ S.E.M. for three or more determinations.
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at ASPET Journals on July 5, 2017 jpet.aspetjournals.org are only 79% identical. The species-specific effects of menthol on hTRPA1 and mTRPA1 have been ascribed to a difference in several residues, including the most critical residue, Val875, in hTRPA1 and its equivalent residue, Gly878, in mTRPA1 (Xiao et al., 2008) . In this position, rTRPA1 and mTRPA1 have the identical residue (i.e., Gly878 in rTRPA1 and mTRPA1), whereas hTRPA1 and rhTRPA1 have the identical residue (i.e., Val875 in hTRPA1 and rhTRPA1). The opposite gating effects of CMP1 on hTRPA1 and rTRPA1 were previously attributed to two S6 transmembrane domain residues (Ser943 and Ile946 in hTRPA1; Ala946 and Met949 in rTRPA1) (Chen et al., 2008) . In these two positions, mTRPA1 has the same residues as rTRPA1, whereas rhTRPA1 has one identical residue (Ile946-rhTRPA1) and one conserved, serine-to-cysteine substation (Cys943-rhTRPA1) compared with hTRPA1. Thus, amino acid differences underlie the observed pharmacological difference between human and rodent channels.
Species-specific differences are a major hurdle for drug discovery efforts targeting TRPA1 (Chen and Kym, 2009 ). Many hTRPA1 antagonists are excluded from further development because they display a differential pharmacology at rodent TRPA1 channels. Such compounds cannot be tested in preclinical studies using conventional rat/mouse models. For these compounds, it is critical to find an alternative species to assess efficacy and expose any onand off-target adverse side effects. Our findings suggest that rhesus monkey could act as a surrogate species for humans in preclinical studies. Various rhesus monkey models have been described in the literature, including ones for thermal nociception (Stevenson et al., 2003) , capsaicin-induced thermal allodynia (Butelman et al., 2004) and hyperalgesia (Hu et al., 2010) , and carrageenan-induced thermal hyperalgesia (Ko and Lee, 2002) . Testing hTRPA1 antagonists for efficacy in rhesus monkey, instead of conventional rat/mouse models, could overcome the serious challenge of species-specific differences and possibly facilitate the development of a selective TRPA1 antagonist for the treatment of pain and neurogenic inflammation.
